Startups
TenSixteen Bio recently came out of stealth mode with $40 million in funding to target somatic mosaicism – particularly clonal hematopoiesis of indeterminate potential (CHIP).
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
Roivant Sciences launches new subsidiary Hemavant that will develop Eisai-licensed asset for transfusion-dependent anemia in patients with low-risk MDS.
Curevo, a clinical-stage biotechnology company, is developing safe and highly-effective vaccines to fight infectious diseases such as shingles.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
Ventus Therapeutics has raised $140 million in a Series C financing round less than two years after launching to develop therapies aimed at diseases of the innate immune system.
The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
San Diego-based Endeavor BioMedicines closed on a Series B financing worth $101 million.
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.
PRESS RELEASES